Xeris Biopharma Holdings Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech and specialty pharma analyst here at Jefferies. I have the wonderful pleasure of having John Shannon and Josh Bennett here from Xeris. Welcome. Thank you. Thank you, Dennis.
Yeah. Maybe to level set everybody, just give us a bit of background around Xeris, and we'll certainly talk about RECORLEV, but just talk about all the progress you guys have made this year.
Xeris is a fast-growing biopharma company. We just raised our guidance with our third quarter earnings to $395 million-$405 million this year. That is 37% growth at the midpoint. We have been carrying that type of growth. It is driven by three products, RECORLEV, which I am sure we are going to talk a lot about for Cushing's, GVOKE, which is basically an EpiPen for diabetics for hypoglycemia, and then KEVEYIS, which is our ultra-rare product for primary periodic paralysis. Those three products with their growth trajectory, we also, at the start of this quarter, we changed our, we put our 2030 outlook. We raised that from just a year and a half ago, we set that at $750 million. We have now raised that to over $1 billion by 2030 with those three products. And then we have one more product in development.
We are about to start the phase III program there, which is XP-8121, which is a once-weekly subcutaneous product for levothyroxine.
Perfect. I will stop there, and I know you got a lot of questions.
I mean, why do not we get started with RECORLEV? I mean, the magnitude of growth has been really impressive, and I know you guys essentially doubled your sales force at the beginning of the year. Talk about how that has gone and talk about also demand and just where that has shaken out.
Recorlev is our growth engine for the company. We doubled our commercial footprint in January. It is our third expansion since we launched this product in 2022. It was a very significant expansion for us. As we look at this marketplace and the opportunity here, there is tremendous growth in more and more people being screened and detected for hypercortisolism, specifically in areas where there is resistant disease. So resistant diabetes, resistant hypertension, resistant obesity. The drugs they are on are not working, and therefore, when you look and find cortisol levels two times above the upper limit of normal, that is usually what the clinicians are looking for, you have found the culprit. There is a lot of movement in this space where more and more clinicians are testing for these patients. Recorlev is benefiting from that information in the marketplace. There is data now that supports that.
Guidelines have recently changed with ADA and EASD, and those are driving even more and more people to screen and detect and driving our growth. Adding our sales organization and expanding them really allows us to get to and scale with the growth in this marketplace, and that really contributed to us really putting Recorlev on a different growth trend in the third quarter. Generally, it would take six to nine months. We saw it come faster and a little more aggressive. That is why we changed a lot of our led to a lot of changes of our longer-term trajectory was because of the Recorlev being on a new growth trend that now we think will get us to a billion-dollar product in three to four years sooner than we said before, which was 2035, so.
Can you give a little bit more color as to the guideline updates and what do guidelines say specifically, and how are you guys capitalizing on that?
Specifically, the guidelines talk about when you, in the case of diabetes, for example, they say if you have resistant diabetes, the insulin is not working, then you should test for cortisol levels. The guidelines basically all point to if you are 1.8 times above the upper limit of normal, then you should treat that cortisol level. Because what we find is when you bring the cortisol levels back to normal range, then the insulin works and other drugs work. So the guidelines are really important because it really helps the next level of primary care. Now, the endocrinologists have been doing this for a couple years now, but now this really opens up other categories, specifically primary care physicians who now have not only the medical guidelines are clear here, but now they have got guidelines all the way down to ADA and EASD.
When your sales reps are out in the field, are they seeing that broadening prescriber base beyond the specialists and into the PCPs?
Yes, that's exactly what's happening. When we do our expansions, there's two things that happen. One is you find more patients within the existing prescribers, but you're finding more targets. That's really what's happening in this space for all three products in this category. Everybody's finding more prescribers as more and more people are testing and screening for cortisol levels.
Okay. Can you comment a little bit about persistence and how long patients are on RECORLEV, and typically by the time they get RECORLEV, have they failed other therapies or have they just been newly diagnosed?
Yeah. Let's start with the majority of the patients that are coming on RECORLEV, more than 60% of them are new news, never been on a medical therapy. There's less and less switching in this space, but most of them are coming as new news, so first time on therapy. Then in terms of persistence, we watch that trend line, but it's not going to change much with so many people new to therapy. The challenge with this space is these are very complex patients to treat, multiple comorbidities. Especially over the first three to four months, people will drop out because a couple things. One is you get cortisol withdrawal. You feel good with cortisol, and you pull that away and start getting in a normal range, people feel that. Plus, you're adjusting all their other meds.
Their hypertensive agents, their diabetes, everything you can imagine that they are on needs to be adjusted when cortisol levels get in normal. There is a lot of If you get through the first three or four months, people will be fine and forever. We have people that have been on RECORLEV for 10 years. You just got to get through those first three to four months in this space, and then hang in there. But we watch our persistence, we watch conversion rates, all those things, and we just keep the trend lines pretty flat when we are adding so many new patients every month, every week, every quarter, that those trend lines are going to hold pretty steady.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
